A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 117-124

  Cobleigh, Melody A ^a   Langmuir, Virginia K ^b   Sledge, George W ^b   Miller, Kathy D ^b   Haney, Latrice ^b   Novotny, William F ^b   Reimann, James D ^b   Vassel, Amy ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEXAMETHASONE; DOXORUBICIN; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ASTHENIA; AXILLARY VEIN; BLEEDING; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; DYSPNEA; EPISTASIS; FEMALE; HEADACHE; HUMAN; HYPERESTHESIA; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INFECTION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METASTASIS; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; OPTIMAL DRUG DOSE; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; SIDE EFFECT; SINUSITIS; SUBCLAVIAN VEIN; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING;

EID: 0242468884     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.013     Document Type: Conference Paper

References (20)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
3. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
4. Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 79:233-269, 1997
5. Ferrara N: Vascular endothelial growth factor: Molecular and biological aspects. Curr Topics Microbiol Immunol 237:1-30, 1999
6. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
7. Gasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
8. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
9. Borgstrom P, Gold DP, Hillan KJ, et al: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with and anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203-4214, 1999
10. Toi M, Inada K, Suzuki H, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
11. Holmgren L, O'Reilly M, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153, 1995
12. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
13. Gordon MS, Margolin K, Talpaz M, et al: Phase 1 safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
14. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001
15. DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
16. Shen BQ, Lee DY, Zioncheck TF: Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057-33063, 1999
17. Granger JP, Alexander BT: Abnormal pressure-natriuresis in hypertension: Role of nitric oxide. Acta Physiol Scand 168:161-168, 2000
18. Henry TD, Rocha-Singh K, Isner JM, et al: Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142:872-880, 2001
19. 165 mediates glomerular endothelial repair. J Clin Invest 104:913-923, 1999
20. Alvarez Arroyo MV, Castilla MA, Gonzalez Pacheco FR, et al: Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 9:1998-2004, 1998